The company J. Craig Venter founded in 1998 to challenge the Human Genome Project ran a data center with 70 terabytes of storage. Venter's latest scheme--creating the world's largest sequencing center--will fill that in less than one week.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
Clinical trials have increased in complexity over the past decade, with sponsors working with an increasing number of sites, countries and service providers. These massive globalized studies place new strains on the organization of essential study documents, collectively known as the trial master file (TMF). In response, vendors have pushed a technological solution: electronic TMF systems.
Vendors pitch eTMFs as a way to easily and securely share clinical study documents with internal and external teams, while also realizing many of the benefits electronic systems have over paper-based processes. Whereas paper files can be lost or destroyed and are only accessible where they are physically located, documents stored in an eTMF are less vulnerable to physical damage and can be viewed from anyplace with access to the web.
POPULAR COMMENT THREADS
Over the past decade a plethora of digital formats have begun competing with print, television, radio and conferences for biopharma marketeers' budgets. And while initial uptake was slow, a survey has now found Big Data, social media and mobile have doubled their share of the marketing mix since 2012.
This week FDA officially introduced its push to open up its data to the public and particularly app developers. The unveiling went over the goals of openFDA, but also detailed some other areas in which the agency is investing. FDA is pushing hard into NGS and cloud-based genomics.
The Global Alliance for Genomics and Health was thrust into the headlines last week when Google joined its ranks. This week it met for the first time to discuss its goals. Development of an open-source public application programming interface (API) for sequencing reads and genetic variants is high on the agenda.
The use of genomics to understand aging has become a high-profile field in recent months, with J. Craig Venter's Human Longevity and Google's Calico both researching the topic. Now Scripps has given the rest of the sector a new resource--whole genome sequences of 454 healthy elderly people.
The account--elilillyco--has posted old photographs of Lilly's facilities and researchers alongside pictures of what its current staff are doing.
During a week in which The Guardian revealed that Britain intercepted and stored webcam images from millions of people, the FDA email snooping revealed in 2012 looks relatively innocent. But Republicans investigating the program think the regulator may have violated whistleblower laws by monitoring employees' emails.
From Our Sister Sites
Pfizer, which boosted production at its plant in Indonesia in 2012, is expanding there again.
With a shortage of ingredients for essential pain drugs looming, there is a fight going on in Australia over whether production of opium poppies can be widened from the island of Tasmania, the source of about half the world's supply.